Ddx17 Mitigates Sepsis‐Induced Cardiomyopathy by Regulating Mitochondrial Dynamics in Cardiomyocytes

Read full text
Authors: Ya‐ting Jiang, Li‐ran Su, Fang‐jing Ni, Luo‐ye Lu, Yuqiang Gong, Jun Luo, Chen-xi Shen, Yang Cao
Cited by: 0
References: 45

Abstract

Sepsis-induced cardiomyopathy (SICM) is a severe complication of sepsis, in which mitochondrial dysfunction contributes to poor outcomes. DEAD-box helicase 17 (Ddx17), a member of the DEAD-box RNA helicase family, is known to regulate mitochondrial function, but its role in SICM remains unclear. In this study, mice with cardiomyocyte-specific Ddx17 knockdown (Ddx17-cKD) and overexpression (Ddx17-OE) were generated, and sepsis models were established using cecal ligation and puncture. Mechanistic findings were further validated in vitro using immunoprecipitation and dual-luciferase assays. Ddx17 expression was markedly reduced in the cardiac tissues of septic mice and in lipopolysaccharide-treated cardiomyocytes. Knockdown of Ddx17 increased mitochondrial reactive oxygen species accumulation, enhanced cell death and decreased superoxide dismutase activity. In contrast, Ddx17 overexpression attenuated mitochondrial apoptosis and oxidative stress, restored adenosine triphosphate production and mitochondrial membrane potential and improved cardiac function in septic mice. Mechanistically, Ddx17 interacted with signal transducer and activator of transcription 3 (STAT3) to suppress transcription of the mitochondrial fission protein dynamin-related protein 1 while maintaining the level of the fusion protein mitofusin 1, thereby preserving mitochondrial integrity and cardiomyocyte homeostasis. These findings demonstrate that Ddx17 protects against sepsis-induced cardiomyopathy by regulating mitochondrial dynamics, reducing oxidative stress and preventing apoptosis, thereby highlighting Ddx17 as a potential therapeutic target for septic cardiac dysfunction.

Fields of Study & Subjects

Mitochondrial Function and Pathology Sepsis Diagnosis and Treatment Cardiac Ischemia and Reperfusion

Publication details

Journal / source
Clinical and Experimental Pharmacology and Physiology
Volume
53
Issue
2
Pages
e70105–e70105
Publication date
1 February 2026
Language
EN